Stock Research for BIIB

BIIB
Current Price

$292.2200


Latest Update: 2018-02-16 16:00:00

High
$ 292.2200
Low
$ 291.6200
Close
$ 291.8700
Volume
148077
 
  

Featured Broker: TradeStation

Get the due diligence for another stock.

 

BIIB Stock Chart & Research Data

The BIIB chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BIIB chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


BIIB Due diligence Resources & Stock Charts

The BIIB stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View BIIB Detailed Price Forecast - CNN Money CNN View BIIB Detailed Summary - Google Finance
Yahoo View BIIB Detailed Summary - Yahoo! Finance Zacks View BIIB Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View BIIB Trends & Analysis - Trade-Ideas Barrons View BIIB Major Holders - Barrons
NASDAQ View BIIB Call Transcripts - NASDAQ Seeking View BIIB Breaking News & Analysis - Seeking Alpha
Spotlight View BIIB Annual Report - CompanySpotlight.com OTC Report View BIIB OTC Short Report - OTCShortReport.com
TradeKing View BIIB Fundamentals - TradeKing Charts View BIIB SEC Filings - Bar Chart
WSJ View Historical Prices for BIIB - The WSJ Morningstar View Performance/Total Return for BIIB - Morningstar
MarketWatch View the Analyst Estimates for BIIB - MarketWatch CNBC View the Earnings History for BIIB - CNBC
StockMarketWatch View the BIIB Earnings - StockMarketWatch MacroAxis View BIIB Buy or Sell Recommendations - MacroAxis
Bullish View the BIIB Bullish Patterns - American Bulls Short Pains View BIIB Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View BIIB Stock Mentions - StockTwits PennyStocks View BIIB Stock Mentions - PennyStockTweets
Twitter View BIIB Stock Mentions - Twitter Invest Hub View BIIB Investment Forum News - Investor Hub
Yahoo View BIIB Stock Mentions - Yahoo! Message Board Seeking Alpha View BIIB Stock Mentions - Seeking Alpha




Financial & Transaction Holdings

SECform4 View Insider Transactions for BIIB - SECform4.com Insider Cow View Insider Transactions for BIIB - Insider Cow
CNBC View BIIB Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for BIIB - OTC Markets
Yahoo View Insider Transactions for BIIB - Yahoo! Finance NASDAQ View Institutional Holdings for BIIB - NASDAQ


Stock Charts

FinViz View BIIB Stock Insight & Charts - FinViz.com StockCharts View BIIB Investment Charts - StockCharts.com
BarChart View BIIB Stock Overview & Charts - BarChart Trading View View BIIB User Generated Charts - Trading View


Latest Financial News for BIIB

Biogen’s key Alzheimer’s disease drug is facing potential signs of trouble
Posted on Saturday February 17, 2018

Because of variability on the clinical trial’s primary endpoint, the company increased the sample size for two ongoing trials. Though it rattled investors, some on Wall Street say it could be a good sign....


How Biogen Inc (NASDAQ:BIIB) Delivered A Better ROE Than Its Industry
Posted on Friday February 16, 2018

Biogen Inc (NASDAQ:BIIB) outperformed the Biotechnology industry on the basis of its ROE – producing a higher 21.19% relative to the peer average of 16.36% over the past 12 months.Read More...


Argus Downgrades Biogen On Trial Delays, Competition In MS, Alzheimer's Drugs
Posted on Friday February 16, 2018

Biogen Inc (NASDAQ: BIIB ) tumbled 8 percent Wednesday after announcing a cohort expansion for its aducanumab Alzheimer’s trials — a change certain to delay results. The news, coupled with expected sales ...


FDA Sets the Stage for Earlier-Stage Alzheimer's Treatments
Posted on Friday February 16, 2018

FDA's proposed guidelines come in a week when major disappointments in the field were announced by companies developing drugs to treat Alzheimer's.


Biogen Drops After Alzheimer's Drug Trial Change Raises Concerns
Bloomberg - Feb 14, 2018
Biogen Inc. plunged after the company said it was making changes to a trial of an Alzheimer's disease drug, after a long list of rival drugs failed.
Biogen's key Alzheimer's disease drug is facing potential signs of trouble - MarketWatch
Biogen shares fall after unexpected 'variability' in Alzheimer's studies - BioPharma Dive

Earnings Preview: What To Expect From Biogen On Thursday
Forbes - Jan 23, 2018
A sign for biotechnology company, Biogen, Inc. is seen on a building in Cambridge, Massachusetts, on March 18, 2017.

Biogen Inc. (BIIB) Dips 2.51% for February 16
Equities.com - Feb 16, 2018
Among the S&P 500's biggest fallers on Friday February 16 was Biogen Inc. (BIIB). The stock experienced a 2.51% decline to $291.87 with 2.93 million shares changing hands.
Argus Downgrades Biogen On Trial Delays, Competition In MS, Alzheimer's Drugs - Benzinga

Biogen: Numbers Are Fine But Valuation Isn't Appealing
Seeking Alpha - Jan 31, 2018
The corporate signals related to the key growth drivers (Tecfidera, Tysabri and Spinraza) have been really solid. However, after the strong performance in the last seven months, a valuation check suggests that the risk/reward is now much less ...

Enter a stock symbol to view the stock details.